Compare SWKH & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWKH | SGHT |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Diversified Financial Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.4M | 187.4M |
| IPO Year | N/A | 2021 |
| Metric | SWKH | SGHT |
|---|---|---|
| Price | $16.70 | $3.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $18.00 | $9.08 |
| AVG Volume (30 Days) | 18.8K | ★ 235.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | $9.18 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.00 | $2.40 |
| 52 Week High | $18.40 | $9.24 |
| Indicator | SWKH | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 32.19 | 48.49 |
| Support Level | $14.69 | $3.29 |
| Resistance Level | $17.08 | $4.29 |
| Average True Range (ATR) | 0.37 | 0.19 |
| MACD | -0.05 | 0.09 |
| Stochastic Oscillator | 12.06 | 69.80 |
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.